https://www.aigom.it/wp-content/uploads/2024/06/ART.25.6.png1205950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-24 07:06:202024-06-24 07:06:20OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2024/06/ART18.6.png1080935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-18 09:01:252024-06-18 09:01:25IMPROVED CLINICAL STAGING SYSTEM FOR LOCALIZED PANCREATIC CANCER USING THE ABC FACTORS: A TAPS CONSORTIUM STUDY
https://www.aigom.it/wp-content/uploads/2024/06/ART11.06.png1257935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-10 08:38:262024-06-10 08:38:26TRASTUZUMAB PLUS GEMCITABINE-CISPLATIN FOR TREATMENT-NAïVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BILIARY TRACT ADENOCARCINOMA: A MULTICENTER, OPEN-LABEL, PHASE II STUDY (TAB)
https://www.aigom.it/wp-content/uploads/2024/06/ART.04.06.png1137935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-03 08:24:502024-06-03 08:24:50PERIOPERATIVE DURVALUMAB FOR RESECTABLE NON-SMALL-CELL LUNG CANCER
https://www.aigom.it/wp-content/uploads/2024/05/ESMOART28.5.png1112935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-23 07:33:562024-05-27 07:38:05REGOMA-OSS: A LARGE, ITALIAN, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF REGORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
https://www.aigom.it/wp-content/uploads/2024/05/art.21.5.png1063935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-17 09:32:042024-05-17 09:32:04FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2024/05/artcolo14.5.png1093958Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-13 08:07:202024-05-13 08:07:20ELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.
https://www.aigom.it/wp-content/uploads/2024/04/ANONCOL.png12441097Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-18 12:22:432024-04-23 08:17:23EVENT-FREE SURVIVAL BY RESIDUAL CANCER BURDEN WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC): EXPLORATORY ANALYSIS FROM KEYNOTE-522
https://www.aigom.it/wp-content/uploads/2024/04/art16.4a.png21701963Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-15 08:41:542024-04-15 08:54:31DOSTARLIMAB FOR PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER.
